- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02184884
Effect of Perioperative Clopidogrel Responsiveness on Ischemic Outcome in Patients With Acute Coronary Syndrome Undergoing Off-pump Coronary Artery Bypass Surgery
The whole blood Thrombelastograph (TEG®) Platelet Mapping™ assay measures clot strength, maximal amplitude (MA), reflecting maximal platelet function, and detects the reduction in platelet function, presented as percentage inhibition, by both aspirin and clopidogrel. A study reported that the TEG® can be used as routine monitoring of the variability in ADP receptor inhibition and of antiplatelet therapy. Therefore, using TEG Platelet Mapping assay, we could find out the perioperative clopidogrel responsiveness of the patients with ACS undergoing OPCAB.
The purpose of this study is to determine whether the rate of the major adverse cardiac events (MACE, a combined endpoint of MI, revascularization and cardiac death) is higher in the patients with high degree of clopidogrel resistance, who are scheduled to undergo the OPCAB due to ACS.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Seoul, Korea, Republic of, 120-752
- Department of Anesthesiology and Pain Medicine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- the patients with ACS undergoing OPCAB
- the patients over 20 years of age
- the patient who have been taking [100 mg of Aspirin] and [75 mg of clopidogrel or 180 mg of ticagrelor] for more than one week and who continue within 3 to 5 days prior to surgery
Exclusion Criteria:
- re-operation or emergency operation
- the patients with bleeding tendency of decreased liver function
- Left ventricular ejection fraction < 40% by echo
- preoperative hematocrit < 33% or platelet count < 100,000/mm3 or creatinine > 1.4 mg/dL
- abnormal preoperative prothrombin time or activated partial thromboplastin time
- preoperative use of other PO antiplatelet drugs or PO anticoagulants
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Control
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
MACE group
the patients with MACE after OPCAB
|
|
no MACE group
the patients without MACE after OPCAB
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of the major adverse cardiac events
Time Frame: at 30 days after surgery
|
major adverse cardiac events(MACE) includes the MI, revascularization and cardiac death.
Rate of the MACE will be higher in the patients with high degree of clopidogrel resistance.
|
at 30 days after surgery
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 4-2014-0172
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Coronary Syndrome (ACS)
-
Uppsala UniversityAbbott Medical Devices; The Medicines Company; InfraredxCompletedAcute Coronary Syndrome (ACS)Sweden
-
The Medicines CompanyCompletedAcute Coronary Syndrome (ACS)United States
-
Canadian Institutes of Health Research (CIHR)Completed
-
Fundación Investigación Sanitaria en LeónAstraZenecaCompleted
-
Hainan People's HospitalRecruiting
-
AstraZenecaCompletedAcute Coronary Syndrome (ACS)China
-
IHF GmbH - Institut für HerzinfarktforschungCompletedAcute Coronary Syndrome (ACS)Germany
-
Bristol-Myers SquibbCompletedAcute Coronary Syndrome (ACS)Canada, Italy, Poland, Sweden, United States, Spain, Austria, Denmark, France, Belgium, Israel, Germany, Russian Federation, United Kingdom
-
The First Affiliated Hospital with Nanjing Medical...Unknown
Clinical Trials on MACE after OPCAB
-
UMC UtrechtSt. Antonius Hospital; IsalaCompletedCoronary Artery DiseaseNetherlands
-
Charles University, Czech RepublicUnknownIschemic Heart Disease | Post-Operative ComplicationsCzech Republic
-
Chinese University of Hong KongRecruitingIron Deficiency AnemiaHong Kong
-
Henry M. Jackson Foundation for the Advancement...U.S. Army Medical Research and Development CommandCompletedTraumatic Brain Injury | Brain ConcussionAfghanistan
-
Northern State Medical UniversityNihon KohdenCompletedPostoperative Complications | Hemodynamic InstabilityRussian Federation
-
Sheffield Teaching Hospitals NHS Foundation TrustIntroMedic USA Inc.CompletedGastrointestinal DiseasesUnited Kingdom
-
Yonsei UniversityUnknownCoronary Artery Disease, DiabetesKorea, Republic of
-
Chipscreen Biosciences, Ltd.Terminated
-
Assistance Publique - Hôpitaux de ParisCompleted
-
University of Sao Paulo General HospitalMount Sinai Hospital, New York; Beneficência Portuguesa de São Paulo; Instituto... and other collaboratorsRecruitingCoronary Artery Disease | Frail ElderlyUnited States, Brazil